UH researchers secure NIH grant to tackle buprenorphine’s dental side effects

In the fatal world of opioid use disorder (OUD), pharmacotherapy, or using a prescribed medication to treat drug dependence, has emerged as the gold standard of treatment.

Short-term alcohol abstinence worsens gut health in alcohol use disorder patients

A study published in PLoS ONE found that short-term abstinence from alcohol in AUD patients exacerbates gut dysbiosis and increases mental distress, contrary to expected

June 14, 2024

One-Year CGM Cleared; Osteoporosis Lawsuits Revived; Chemicals and Early Puberty

The FDA cleared Eversense 365 as the first 1-year integrated continuous glucose monitoring (CGM) system for adults with type 1 or type 2 diabetes, said

September 25, 2024

DEA Announces Major Increase to 2023 Production Quotas for Psilocybin, THC and Ibogaine | Psychedelic Invest

The U.S. Drug Enforcement Administration (DEA) is proposing a “dramatic increase” in this year’s production quotas for psychedelics ibogaine and psilocybin as well as marijuana

November 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.